The study is early-stage and non-interventional, providing no near-term revenue or approval catalyst. Traders should expect limited price impact from this filing alone. Monitor for study results, FDA submission milestones, or financing needs given the pre-revenue status.
Price Chart
Executive Summary
Polyrizon announced a human study for its NASARIX allergy blocker to measure nasal residence time, in collaboration with a European academic medical center and a CRO. This is a non-interventional characterization study supporting the V&V program and regulatory pathway. As a development-stage biotech with immaterial revenue and a $21M market cap, this represents incremental pipeline progress but no fundamental change in valuation.
Key Facts
- Polyrizon executed an agreement with a leading European university medical center and a CRO for a human study of NASARIX (PL-14) Allergy Blocker.
- The study is a human performance and characterization study to evaluate nasal residence time, not an interventional safety/efficacy trial.
- The study will be conducted under EU MDR and GCP, involving healthy participants with endoscopic visualization.
- The study is part of Polyrizon's V&V program and intended to support FDA regulatory submissions.
- No financial terms, timeline, enrollment numbers, or concrete milestones were disclosed.
- Company is a development-stage biotech with $21M market cap; no revenue or financial data in this filing.
Financial Impact
No financial data disclosed; no revenue or cash flow information in this filing.
Risk Factors
- Study may fail to demonstrate meaningful residence time, delaying regulatory progress.
- No disclosed timeline; study has not yet commenced (awaiting ethics committee authorization).
- Company has limited cash runway and may require dilutive financing (active F-3 shelf registration noted in cross-filings).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-068760 |
| Document: ea0294757-6k_polyrizon.htm | 0001213900-26-068760 |
| Document: 0001213900-26-068760-index-headers.html | 0001213900-26-068760 |
| Document: 0001213900-26-068760-index.html | 0001213900-26-068760 |
| Document: 0001213900-26-068760.txt | 0001213900-26-068760 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Press Release | $9.01 | awaiting T+1 | — | $8.96 (−0.59%) |
Oct 5, 2026 21d ago | 6-K | $9.67 $9.15 | ▼ −5.37% | ▼ −5.13% | $8.96 (−7.37%) |
Oct 2, 2026 25d ago | EFFECT | $9.61 $9.26 | ▲ +3.64% | ▲ +4.32% | $8.96 (+6.80%) |
Sep 22, 2026 4w ago | Press Release | $10.66 $11.16 | ▲ +4.69% | ▲ +5.41% | $8.96 (−15.98%) |
Sep 18, 2026 5w ago | F-1 | $10.90 $10.66 | ▲ +2.20% | ▲ +2.19% | $8.96 (+17.83%) |
Sep 4, 2026 7w ago | Press Release | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Sep 4, 2026 7w ago | 6-K | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Sep 4, 2026 7w ago | 424B5 | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Aug 20, 2026 9w ago | 6-K | $10.30 $10.70 | ▲ +3.88% | ▲ +4.18% | $8.96 (−13.04%) |
Jul 13, 2026 15w ago | 6-K | $13.76 $13.07 | ▼ −4.98% | ▼ −5.38% | $8.96 (−34.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers